Participation of Opioid Pathway in the Central Antinociceptive Effects of Eugenol
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The aim of the present study was to evaluate the central antinociceptive effects of eugenol after intraperitoneal administration. Experiments were carried out using male Sprague-Dawley rats. Subcutaneous injection of 5% formalin-induced nociceptive behavioral responses was used as the pain model. Subcutaneous injection of 5% formalin significantly produced nociceptive responses by increasing the licking time during nociceptive behavior. Subsequent intraperitoneal injection of 100 mg/kg of eugenol led to a significant decrease in the licking time. However, low dose of eugenol (50 mg/kg) did not affect the nociceptive behavioral responses produced by subcutaneous injection of formalin. Intrathecal injection of 30 μg of naloxone, an opioid receptor antagonist, significantly blocked antinociceptive effects produced by intraperitoneal injection of eugenol. Neither intrathecal injection of methysergide (30 μg), a serotonin receptor antagonist nor phentolamine (30 μg), an α-adrenergic receptor antagonist influenced antinociceptive effects of eugenol, as compared to the vehicle treatment. These results suggest that central opioid pathway participates in mediating the antinociceptive effects of eugenol.
Abstract
The aim of the present study was to evaluate the central antinociceptive effects of eugenol after intraperitoneal administration. Experiments were carried out using male Sprague-Dawley rats. Subcutaneous injection of 5% formalin-induced nociceptive behavioral responses was used as the pain model. Subcutaneous injection of 5% formalin significantly produced nociceptive responses by increasing the licking time during nociceptive behavior. Subsequent intraperitoneal injection of 100 mg/kg of eugenol led to a significant decrease in the licking time. However, low dose of eugenol (50 mg/kg) did not affect the nociceptive behavioral responses produced by subcutaneous injection of formalin. Intrathecal injection of 30 μg of naloxone, an opioid receptor antagonist, significantly blocked antinociceptive effects produced by intraperitoneal injection of eugenol. Neither intrathecal injection of methysergide (30 μg), a serotonin receptor antagonist nor phentolamine (30 μg), an α-adrenergic receptor antagonist influenced antinociceptive effects of eugenol, as compared to the vehicle treatment. These results suggest that central opioid pathway participates in mediating the antinociceptive effects of eugenol.
참고문헌 (46)
- Li W, "Inhibitory action of eugenol compounds on the production of nitric oxide in RAW264.7 macrophages", Biomed Res, 27, pp.69~74 (2006)[DOI]
- Kim SS, "Eugenol suppresses cyclooxygenase-2 expression in lipopolysaccharide-stimulated mouse macrophage RAW 264.7 cells", Life Sci, 73, pp.337~348 (2003)[DOI]
- Briseno BM, "Root canal sealer cytotoxicity on human gingival fibroblasts. 1. Zinc oxide-eugenol-based sealers", J Endod, 16, pp.383~386 (1990)[DOI]
- Goerig AC, "The pulpal response to ZOE with stock eugenol versus ZOE with purified eugenol", Oral Surg Oral Med Oral Pathol, 50, pp.557~562 (1980)[DOI]
- Horsted P, "Capping of monkey pulps with Dycal and a Ca-eugenol cement", Oral Surg Oral Med Oral Pathol, 52, pp.531~553 (1981)[DOI]
- Koh T, "Re-evaluation of anti-inflammatory potential of eugenol in IL-<TEX>$1{\beta}$<", TEX>-stimulated gingival fibroblast and pulp cells, 2013, pp.27, 269~273
- Hansen EK, "Influence of temporary filling materials on effect of dentin-bonding agents", Scand J Dent Res, 95, pp.516~520 (1987)
- Anpo M, "Cytotoxic effect of eugenol on the expression of molecular markers related to the osteogenic differentiation of human dental pulp cells", Odontology, 99, pp.188~192 (2011)[DOI]
- Fujisawa S, "Interaction between 2-ethoxybenzoic acid (EBA) and eugenol, and related changes in cytotoxicity", J Dent Res, 82, pp.43~47 (2003)[DOI]
- Wie MB, "Eugenol protects neuronal cells from excitotoxic and oxidative injury in primary cortical cultures", Neurosci Lett, 225, pp.93~96 (1997)[DOI]
- Irie Y, "Rhizoma acori graminei and its active principles protect PC-12 cells from the toxic effect of amyloid- <TEX>${\beta}$<", TEX> peptide, 2003, pp.963, 282~289
- Won MH, "Postischemic hypothermia induced by eugenol protects hippocampal neurons from global ischemia in gerbils", Neurosci Lett, 254, pp.101~104 (1998)[DOI]
- Nangle MR, "Effects of eugenol on nerve and vascular dysfunction in streptozotocin- diabetic rats", Planta Med, 72, pp.494~500 (2006)[DOI]
- Norte MC, "Effects of methyl- eugenol administration on behavioral models related to depression and anxiety, in rats", Phytomedicin, 12, pp.294~298 (2005)[DOI]
- Carlini EA, "Methyleugenol as a surgical anesthetic in rodents", Experientia, 37, pp.588~589 (1981)[DOI]
- Sell AB, "Anesthetic action of methyleugenol and other eugenol derivatives", Pharmacology, 14, pp.367~377 (1976)[DOI]
- Guenette SA, "Pharmacokinetics and anesthetic activity of eugenol in male Sprague-Dawley rats", J Vet Pharmacol Ther, 30, pp.91~92 (2007)[DOI]
- Kozam G, "The effect of eugenol on nerve transmission", Oral Surg Oral Med Oral Pathol, 44, pp.799~805 (1977)[DOI]
- Yano S, "Antinociceptive effect of methyleugenol on formalin-induced hyperalgesia in mice", Eur J Pharmacol, 553, pp.99~103 (2006)[DOI]
- Wang ZJ, "7 channels by methyl eugenol as a mechanism underlying its antinociceptive and anesthetic actions", Acta Pharmacol Sin, 36, pp.791~799 (2015)[DOI]
- Chung G, "Activation of transient receptor potential ankyrin 1 by eugenol", Neuroscience, 261, pp.153~160 (2014)[DOI]
- Park CK, "Molecular mechanism for local anesthetic action of eugenol in the rat trigeminal system", Pain, 144, pp.84~94 (2009)[DOI]
- Abbott FV, "The formalin test: scoring properties of the first and second phases of the pain response in rats", Pain, 60, pp.91~102 (1995)[DOI]
- Choi HS, "Effects of TNF-alpha injected intracisternally on the nociceptive jaw-opening reflex and orofacial formalin test in freely moving rats", Prog Neuropsychopharmacol Biol Psychiatry, 27, pp.613~618 (2003)[DOI]
- Choi HS, "Effects of intracisternal injection of interleukin-6 on nociceptive jaw opening reflex and orofacial formalin test in freely moving rats", Brain Res Bull, 59, pp.365~370 (2003)[DOI]
- Raboisson P, "The orofacial formalin test", Neurosci Biobehav Rev, 28, pp.219~226 (2004)[DOI]
- Ahn DK, "Intracisternal administration of chemokines facilitated formalin-induced behavioral responses in the orofacial area of freely moving rats", Brain Res Bull, 66, pp.50~58 (2005)[DOI]
- Yang GY, "Intracisternal administration of NR2 antagonists attenuates facial formalin-induced nociceptive behavior in rats", J Orofac Pain, 24, pp.203~211 (2010)
- Tjolsen A, "The formalin test: an evaluation of the method", Pain, 51, pp.5~17 (1992)[DOI]
- Raboisson P, "Effects of subcutaneous formalin on the activity of trigeminal brain stem nociceptive neurones in the rat", J Neurophysiol, 73, pp.496~505 (1995)[DOI]
- Jeon HJ, "Intracisternal administration of NR2 subunit antagonists attenuates the nociceptive behavior and p-p38 MAPK expression produced by compression of the trigeminal nerve root", Mol Pain, 7, pp.46~ (2011)
- Won KA, "The glial-neuronal GRK2 pathway participates in the development of trigeminal neuropathic pain in rats", J Pain, 15, pp.250~261 (2014)[DOI]
- Jorkjend L, "Effect of non-eugenol- and eugenol-containing periodontal dressings on the incidence and severity of pain after periodontal soft tissue surgery", J Clin Periodontol, 17, pp.341~344 (1990)[DOI]
- Hodosh AJ, "Potassium nitrate-zinc oxide eugenol temporary cement for provisional crowns to diminish postpreparation tooth pain", J Prosthet Dent, 70, pp.493~495 (1993)[DOI]
- Brodin P, "Differential inhibition of A, B and C fibres in the rat vagus nerve by lidocaine, eugenol and formaldehyde", Arch Oral Biol, 30, pp.477~480 (1985)[DOI]
- Hai Ying Li, "Eugenol Inhibits ATP-induced P2X Currents in Trigeminal Ganglion Neurons", The Korean Journal of Physiology & Pharmacology, 12(6), pp.315~321 (2008), 대한약리학회
- Cho JS, "Effects of eugenol on Na+ currents in rat dorsal root ganglion neurons", Brain Res, 1243, pp.53~62 (2008)[DOI]
- Basbaum AI, "Endogenous pain control mechanisms: review and hypothesis", Ann Neurol, 4, pp.451~462 (1978)[DOI]
- Basbaum AI, "Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry", Annu Rev Neurosci, 7, pp.309~338 (1984)[DOI]
- Reynolds DV, "Surgery in the rat during electrical analgesia induced by focal brain stimulation", Science, 164, pp.444~445 (1969)[DOI]
- Mayer DJ, "Analgesia from electrical stimulation in the brainstem of the rat", Science, 174, pp.1351~1354 (1971)[DOI]
- Llewelyn MB, "The effect of modification of 5-hydroxytryptamine function in nucleus raphe magnus on nociceptive threshold", Brain Res, 306, pp.165~170 (1984)[DOI]
- Ossipov MH, "Locus coeruleus lesions in the rat enhance the antinociceptive potency of centrally administered clonidine but not morphine", Brain Res, 341, pp.320~330 (1985)[DOI]
- Simson PE, "Alpha-2 receptor blockade increases responsiveness of locus coeruleus neurons to excitatory stimulation", J Neurosci, 7, pp.1732~1740 (1987)[DOI]
- Watkins LR, "Organization of endogenous opiate and nonopiate pain control systems", Science, 216, pp.1185~1192 (1982)[DOI]
- Ohkubo T, "The selective capsaicin antagonist capsazepine abolishes the antinociceptive action of eugenol and guaiacol", J Dent Res, 76, pp.848~851 (1997)[DOI]
